Atrial fibrillation in elderly patients with heart failure: convergence of two cardiovascular epidemics in the 21st Century

References

• Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stoke prevention: the Anticoagulation and Risk Factors in Atrial fibrillation (ATRIA) study. JAMA281(18), 2370–2375 (2001).
   Google Scholar
• Roger VL, Go AS, Lloyd-Jones DM et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2011 update: a report from the American Heart Association. Circulation123(4), e18–e209 (2011).
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Wang TJ, Leip EP et al. Lifetime risk for developing atrial fibrillation: the Framingham heart study. Circulation110, 1042–1036 (2004).
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Larson MG, Leip EP et al. Lifetime risk for developing congestive heart failure: the Framingham heart study. Circulation106, 3068–3072 (2002).
   PubMed Web of Science ®Google Scholar
• Kannel WB, Benjamin EJ. Current perceptions in the epidemiology of atrial fibrillation. Cardiol. Clinic27, 13–24 (2009).
   PubMedGoogle Scholar
• Kannel WB, Benjamin EJ. Epidemiology of heart failure. Am. Heart J.121, 951–957 (1991).
   PubMed Web of Science ®Google Scholar
• Lee WC, Lamas GA, Balu S. Direct treatment cost of atrial fibrillation in the elderly American population: a Medicare perspective. J. Med. Econ.11, 281–298 (2008).
   PubMedGoogle Scholar
• Benjamin EJ, Levy D, Vaziri SM et al. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA271, 840–844 (1994).
   PubMed Web of Science ®Google Scholar
• Wang TJ, Larson MG, Levy D et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham heart study. Circulation107, 2920–2925 (2003).
   PubMed Web of Science ®Google Scholar
• Cleland JGF, Chattopadhyay S, Khand A et al. Prevalence and incidence of arrhythmias and sudden death in heart failure. Heart Fail. Rev.7, 229–242 (2002).
   PubMedGoogle Scholar
• Savalieva I, Camm AJ. Atrial fibrillation and heart failure: natural history and pharmacologic treatment. Europace5, S5–S19 (2004).
   Google Scholar
• McMurray JJ, Carson PE, Komajda M et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur. J. Heart Fail.10, 149–157 (2008).
   PubMed Web of Science ®Google Scholar
• De Ferrari GM, Klersy C, Ferrero P et al. Atrial fibrillation in heart failure patients: prevalence in daily practice and effects on the severity of symptoms. Data from the ALPHA study registry. Eur. J. Heart Fail.9, 502–509 (2007).
   PubMed Web of Science ®Google Scholar
• Ruo B, Capra AM, Jensvold NG et al. Racial variation in the prevalence of atrial fibrillation in patients with heart failure: the EPOCH study. J. Am. Coll. Cardiol.43, 429–435 (2004).
   PubMed Web of Science ®Google Scholar
• Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology and rationale for therapy. Am. J. Cardiol.91(Suppl.), 2D–8D (2003).
   PubMed Web of Science ®Google Scholar
• De Souza AI, Cardin S, Wait R et al. Proteomic and metabolic analysis of atrial profibrillatory remodeling in congestive heart failure. J. Mol. Cell Cardiol.49, 851–863 (2010).
   Google Scholar
• Shinbane JS, Wood MA, Jensen DA et al. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J. Am. Coll. Cardiol.29, 709–715 (1997).
   PubMed Web of Science ®Google Scholar
• Parthenakis FI, Patrianakos AP, Skalidis EI et al. Atrial fibrillation is associated with increased neurohormonal activation and reduced exercise tolerance in patients with non-ischemic dilated cardiomyopathy. Int. J. Cardiol.118, 206–214 (2007).
   Google Scholar
• Mancini DM, Eisen H, Kussmaul W et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation83, 778–786 (1991).
   PubMed Web of Science ®Google Scholar
• Arena R, Myers J, Abella J et al. Development of a ventilatory classification system in patients with heart failure. Circulation115, 2410–2417 (2007).
   PubMed Web of Science ®Google Scholar
• Agostoni P, Emdin M, Corra U et al. Permanent atrial fibrillation affects exercise capacity in chronic heart failure patients. Eur. Heart J.29, 2367–2372 (2008).
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Wolf PA, D’Agostino RB et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation98, 946–952 (1998).
   PubMed Web of Science ®Google Scholar
• Carsons PE, Johnson GR, Dunkman WB et al. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT studies. Circulation87(Suppl. 6), VI1102–VI1110 (1993).
   Google Scholar
• Crijns HJGM, Tjeerdsma G, de Kam PJ et al. Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. Eur. Heart J.21, 1238–1245 (2000).
   PubMed Web of Science ®Google Scholar
• Middlekauf HR, Stevenson WG, Stevenson LW. Prognostic significance of atrial fibrillation in advanced heart failure: a study of 390 patients. Circulation84, 40–48 (1991).
   PubMed Web of Science ®Google Scholar
• Dries DL, Exner DV, Gersh BJ et al. Atrial fibrillation is associated with an increased risk of mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular dysfunction: a retrospective analysis of the SOLVD trials. J. Am. Coll. Cardiol.32, 695–703 (1998).
   PubMed Web of Science ®Google Scholar
• Olson LG, Swedberg K, Ducharme A et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction. J. Am. Coll. Cardiol.47, 1997–2004 (2006).
   Google Scholar
• Pedersen OD, Sondergaard P, Nielsen T et al. Atrial fibrillation, ischemic heart disease, and the risk of death in patients with heart failure. Eur. Heart J.27, 2866–2870 (2006).
   PubMed Web of Science ®Google Scholar
• Raunso J, Pedersen OD, Dominguez H et al. Atrial fibrillation in heart failure is associated with an increased risk of death only in patients with ischaemic heart disease. Eur. J. Heart Fail.12, 692–697 (2010).
   PubMed Web of Science ®Google Scholar
• Wyde DG, Waldo AL, DiMarco JP et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med.347, 1825–1833 (2002).
   Google Scholar
• Van Gelder IC, Hagens VE, Bosker HA et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N. Engl. J. Med.347, 1834–1840 (2002).
   PubMed Web of Science ®Google Scholar
• Freudenberger RS, Wilson AC, Kostis JB et al. Comparison of rate vs rhythm control for atrial fibrillation in patients with left ventricular dysfunction (from the AFFIRM study). Am. J. Cardiol.100, 247–252 (2007).
   PubMed Web of Science ®Google Scholar
• Hagens VE, Crijns HJ, Van Veldhuisen DJ et al. Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate atrial fibrillation: results from the rate control versus electrical cardioversion (RACE) study. Am. Heart J.149, 1106–1111 (2005).
   PubMed Web of Science ®Google Scholar
• Roy D, Talajic M, Nattel S et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N. Engl. J. Med.358, 2667–2677 (2008).
   PubMed Web of Science ®Google Scholar
• Shelton RJ, Clark AL, Goode K et al. A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II Study). Heart95, 924–930 (2009).
   PubMed Web of Science ®Google Scholar
• Kong MH, Shaw LK, O’Connor CM et al. Is rhythm-control superior to rate-control in patients with atrial fibrillation and diastolic dysfunction? Ann. Noninv. Electocard.15, 209–217 (2010).
   Google Scholar
• Goldenberg IF, Lewis WR, Dias VC et al. Intravenous diltiazem for the treatment of patients with atrial fibrillation or flutter and moderate to severe congestive cardiac failure. Am. J. Cardiol.74, 884–889 (1994).
   PubMed Web of Science ®Google Scholar
• Heywood JT, Graham B, Marais GE et al. Effects of intravenous diltiazem on rapid atrial fibrillation accompanied by congestive heart failure. Am. J. Cardiol.67, 1150–1152 (1991).
   PubMed Web of Science ®Google Scholar
• Hou ZY, Chang MS, Chen CY et al. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. Eur. Heart J.16, 521–528 (1995).
   PubMed Web of Science ®Google Scholar
• Khand AU, Rankin AC, Kaye GC et al. Systematic review of the management of atrial fibrillation in patients with heart failure. Eur. Heart J.21, 614–632 (2000).
   PubMedGoogle Scholar
• Khand AU, Rankin AC, Martin W et al. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in heart failure? J. Am. Coll. Cardiol.42, 1944–1951 (2003).
   PubMed Web of Science ®Google Scholar
• Prakash PC, Singh BM, Ellenbogen K et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation. Circulation98, 2574–2579 (1998).
   Google Scholar
• Massie BM, Fisher SG, Radford M et al. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. CHF-STAT investigators. Circulation93, 2128–2134 (1996).
   PubMed Web of Science ®Google Scholar
• Brignole M, Menozzi C, Gianfranchi L et al. Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation. Circulation98, 953–960 (1998).
   PubMed Web of Science ®Google Scholar
• Doshi RN, Daoud EG, Fellows C et al. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J. Cardiovasc. Electrophys.16, 1160–1165 (2005).
   Web of Science ®Google Scholar
• Van Gelder IC, Groenveld HF, Crijns HJ et al. Lenient versus strict rate control in patients with atrial fibrillation. N. Engl. J. Med.362, 1363–1373 (2010).
   PubMed Web of Science ®Google Scholar
• Pedersen OD, Bagger H, Keller N et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function. Circulation104(3), 292–296 (2001).
   PubMed Web of Science ®Google Scholar
• Singh BN, Connolly BJ, Crijns HJ et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N. Engl. J. Med.357, 987–999 (2007).
   PubMed Web of Science ®Google Scholar
• Kober L, Torp-Pedersen C, McMurray JJ et al. Increased mortality after dronedarone therapy for severe heart failure. N. Engl. J. Med.358, 2678–2687 (2008).
   PubMed Web of Science ®Google Scholar
• Hsu LF, Jais P, Sanders P et al. Catheter ablation for atrial fibrillation in congestive heart failure. N. Engl. J. Med.351, 2373–2383 (2004).
   PubMed Web of Science ®Google Scholar
• Ad N, Henry L, Hunt S. The impact of surgical ablation in patients with low ejection fraction, heart failure and atrial fibrillation. Eur. J. Cardiothorac. Surg.40(1), 70–76 (2011).
   Google Scholar
• Khan MN, Jais P, Cummings J et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N. Engl. J. Med.359, 1778–1785 (2008).
   PubMed Web of Science ®Google Scholar
• Young JB, Abraham WT, Smith AL et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure. JAMA289, 2685–2694 (2003).
   PubMed Web of Science ®Google Scholar
• Moss AJ, Hall WJ, Cannom DS et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N. Engl. J. Med.361, 1329–1338 (2009).
   PubMed Web of Science ®Google Scholar
• Tang ASL, Wells GA, Talajic M et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N. Engl. J. Med.363, 2385–2395 (2010).
   PubMed Web of Science ®Google Scholar
• Gasparini M, Steinberg JS, Arshad A et al. Resumption of sinus rhythm in patients with heart failure and permanent atrial fibrillation undergoing cardiac resynchronization therapy: a longitudinal observational study. Eur. Heart J.31, 976–983 (2010).
   PubMedGoogle Scholar
• Upadhyay GA, Choudhry NK, Auricchio A et al. Cardiac resynchronization in patients with atrial fibrillation: a meta-analysis of prospective cohort studies. J. Am. Coll. Cardiol.52, 1239–1246 (2008).
   PubMed Web of Science ®Google Scholar
• Santini M, Gasparini M, Landolina M et al. Device-detected atrial tachyarrhythmias predict adverse outcome in real-world patients with implantable biventricular defibrillators. J. Am. Coll. Cardiol.57, 167–172 (2011).
   PubMed Web of Science ®Google Scholar
• Glotzer TV, Daoud EG, Wyse DG et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk. Circ. Arrhythm. Electrophysiol.2, 474–480 (2009).
   PubMed Web of Science ®Google Scholar
• Lip GY, Gibbs CR. Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm: a Cochrane systematic review. QJM95, 419–421 (2002).
   Google Scholar
• Waldo AL. Anticoagulation: stroke prevention in patients with atrial fibrillation. Cardiol. Clinic27, 125–135 (2009).
   Google Scholar
• Piccini JP, Hernandez AF, Zhao X et al. Quality of care for atrial fibrillation among patients hospitalized for heart failure. J. Am. Coll. Cardiol.54, 1280–1289 (2009).
   PubMed Web of Science ®Google Scholar
• Mant J, Hobbs FD, Fletcher K et al.; BAFTA investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet370, 493–503 (2007).
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Wallentin L, Connolly SJ et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial. Circulation123, 2363–2372 (2011).
   PubMed Web of Science ®Google Scholar